Results of CHOP chemotherapy for diffuse large B-cell lymphoma
Patients with diffuse large B-cell lymphoma treated in a University Hospital were studied from 1990 to 2001. Two treatment regimens were used: ProMACE-CytaBOM and then, from November 1996 on, the CHOP regimen. Complete remission (CR), disease-free survival (DFS), and overall survival (OS) rates were...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Associação Brasileira de Divulgação Científica
2006-10-01
|
| Series: | Brazilian Journal of Medical and Biological Research |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001000007 |
| _version_ | 1811210346569924608 |
|---|---|
| author | A.E. Hallack Neto J. Pereira B. Beitler D.A.F. Chamone P.D. Llacer F.L. Dulley M.C.M.A. Macedo A. Chaoubah |
| author_facet | A.E. Hallack Neto J. Pereira B. Beitler D.A.F. Chamone P.D. Llacer F.L. Dulley M.C.M.A. Macedo A. Chaoubah |
| author_sort | A.E. Hallack Neto |
| collection | DOAJ |
| description | Patients with diffuse large B-cell lymphoma treated in a University Hospital were studied from 1990 to 2001. Two treatment regimens were used: ProMACE-CytaBOM and then, from November 1996 on, the CHOP regimen. Complete remission (CR), disease-free survival (DFS), and overall survival (OS) rates were determined. Primary refractory patients and relapsed patients were also assessed. A total of 111 patients under 60 years of age were assessed and ranked according to the international prognostic index adjusted to age. Twenty (18%) of them were classified as low risk, 40 (36%) as intermediate risk, 33 (29.7%) as high intermediate risk, and 18 (16.3%) as high risk. Over a five-year period, OS and DFS rates were 71 and 59%, respectively, for all patients. For the same time period, OS and DFS rates were 72.8 and 61.3%, respectively, for 77 patients treated with CHOP chemotherapy and 71.3 and 60% for patients treated with the ProMACE-CytaBOM protocol. There was no significant difference in OS or DFS between the two groups. Eleven of 50 refractory and relapsed patients were consolidated with high doses of chemotherapy. Three received allogenic and 8 autologous bone marrow transplantation. For the latter, CR was 62.5% and mean OS was 41.1 months. The clinical behavior, CR, DFS, and OS of the present patients were similar to those reported in the literature. We conclude that both the CHOP and ProMACE-CytaBOM protocols can be used to treat diffuse large B-cell lymphoma patients, although the CHOP protocol is preferable because of its lower cost and lower toxicity. |
| first_indexed | 2024-04-12T04:53:55Z |
| format | Article |
| id | doaj.art-c011c811540449859dc61457bcf33bbb |
| institution | Directory Open Access Journal |
| issn | 0100-879X 1414-431X |
| language | English |
| last_indexed | 2024-04-12T04:53:55Z |
| publishDate | 2006-10-01 |
| publisher | Associação Brasileira de Divulgação Científica |
| record_format | Article |
| series | Brazilian Journal of Medical and Biological Research |
| spelling | doaj.art-c011c811540449859dc61457bcf33bbb2022-12-22T03:47:12ZengAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research0100-879X1414-431X2006-10-01391013151322Results of CHOP chemotherapy for diffuse large B-cell lymphomaA.E. Hallack NetoJ. PereiraB. BeitlerD.A.F. ChamoneP.D. LlacerF.L. DulleyM.C.M.A. MacedoA. ChaoubahPatients with diffuse large B-cell lymphoma treated in a University Hospital were studied from 1990 to 2001. Two treatment regimens were used: ProMACE-CytaBOM and then, from November 1996 on, the CHOP regimen. Complete remission (CR), disease-free survival (DFS), and overall survival (OS) rates were determined. Primary refractory patients and relapsed patients were also assessed. A total of 111 patients under 60 years of age were assessed and ranked according to the international prognostic index adjusted to age. Twenty (18%) of them were classified as low risk, 40 (36%) as intermediate risk, 33 (29.7%) as high intermediate risk, and 18 (16.3%) as high risk. Over a five-year period, OS and DFS rates were 71 and 59%, respectively, for all patients. For the same time period, OS and DFS rates were 72.8 and 61.3%, respectively, for 77 patients treated with CHOP chemotherapy and 71.3 and 60% for patients treated with the ProMACE-CytaBOM protocol. There was no significant difference in OS or DFS between the two groups. Eleven of 50 refractory and relapsed patients were consolidated with high doses of chemotherapy. Three received allogenic and 8 autologous bone marrow transplantation. For the latter, CR was 62.5% and mean OS was 41.1 months. The clinical behavior, CR, DFS, and OS of the present patients were similar to those reported in the literature. We conclude that both the CHOP and ProMACE-CytaBOM protocols can be used to treat diffuse large B-cell lymphoma patients, although the CHOP protocol is preferable because of its lower cost and lower toxicity.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001000007Diffuse large B-cell lymphomaCHOP lymphoma treatmentProMACE-CytaBOM treatment |
| spellingShingle | A.E. Hallack Neto J. Pereira B. Beitler D.A.F. Chamone P.D. Llacer F.L. Dulley M.C.M.A. Macedo A. Chaoubah Results of CHOP chemotherapy for diffuse large B-cell lymphoma Brazilian Journal of Medical and Biological Research Diffuse large B-cell lymphoma CHOP lymphoma treatment ProMACE-CytaBOM treatment |
| title | Results of CHOP chemotherapy for diffuse large B-cell lymphoma |
| title_full | Results of CHOP chemotherapy for diffuse large B-cell lymphoma |
| title_fullStr | Results of CHOP chemotherapy for diffuse large B-cell lymphoma |
| title_full_unstemmed | Results of CHOP chemotherapy for diffuse large B-cell lymphoma |
| title_short | Results of CHOP chemotherapy for diffuse large B-cell lymphoma |
| title_sort | results of chop chemotherapy for diffuse large b cell lymphoma |
| topic | Diffuse large B-cell lymphoma CHOP lymphoma treatment ProMACE-CytaBOM treatment |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001000007 |
| work_keys_str_mv | AT aehallackneto resultsofchopchemotherapyfordiffuselargebcelllymphoma AT jpereira resultsofchopchemotherapyfordiffuselargebcelllymphoma AT bbeitler resultsofchopchemotherapyfordiffuselargebcelllymphoma AT dafchamone resultsofchopchemotherapyfordiffuselargebcelllymphoma AT pdllacer resultsofchopchemotherapyfordiffuselargebcelllymphoma AT fldulley resultsofchopchemotherapyfordiffuselargebcelllymphoma AT mcmamacedo resultsofchopchemotherapyfordiffuselargebcelllymphoma AT achaoubah resultsofchopchemotherapyfordiffuselargebcelllymphoma |